Introduction
Aseptic loosening (AL) is the most important problem in total hip arthroplasty (THA). It is responsible for approximately 70 % of implant failures [1] . AL is a particle-induced osteolysis resulting from a foreign-body granulomatous response to wear of the implant, leading to macrophage and osteoclast-mediated bone resorption with suppression of osteoblast activity or bone formation process [2] . Many cytokines or biomarkers have been found to be relevant to AL of THA, such as the macrophage related tumour necrosis factor (TNF)-α or interleukin (IL)-1β [3, 4] , the osteoclast related receptor activator of nuclear factor-kappaB ligand (RANKL) and its suppressor osteoprotegerin (OPG) on the surface of osteoblast [5] , and the bone resorption marker cross-linked N-terminal telopeptide (NTX) and bone formation marker procollagen I C-terminal extension peptide (PICP) [6] . But these results are controversial, and there is no study to compare all these important biomarkers of AL simultaneously which makes it difficult to be sure of their effects in AL of THA.
On the other hand, early detection of osteolysis or loosening in THA is difficult. The diagnosis is mainly based on clinical history, physical examination, and imaging. Current methods are unable to detect early AL, require radioactive testing, or are expensive [7] . Since there are many sensitive biomarkers related to AL, we postulate that synesthetic biomarker analysis could more effectively detect AL than any single biomarker and even traditional X-ray examination. We therefore evaluated the systemic biomarkers of osteolysis or bone remodelling in the early detection of periprosthetic AL.
Material and methods
This study protocol was approved by the institutional Ethical Committee on human research and is in compliance with the Helsinki Declaration of 1975, as revised in 1996.
Study participants
Blood samples from 100 subjects were collected. Thirty-one patients had failed THA due to AL, and were candidates for revision THA (late AL group). Fifteen patients had undergone THA and had clinical and radiographic evidence of AL (early AL group). Nineteen patients had prosthetic THA that was clinically and radiographically stable (stable group). The remaining 35 individuals were clinically normal volunteers (healthy donor group) who in the last month had not taken any medication. The follow-up period was more than two years, in order to exclude changes of bone turnover associated with arthroplasty [7] . All four groups were age-and sex-matched. Patients affected by metabolic bone disease, rheumatoid arthritis, autoimmune disease, or malignant tumour around the arthroplasty were excluded from the study. Routine pre-operative blood testing, ESR, C reactive protein, and intraoperative histological testing were also used to exclude the presence of infection.
For the 34 patients in the early AL and stable groups, the indications for total hip arthroplasty were femoral aseptic necrosis (12/34, 35 %), idiopathic osteoarthritis (9/34, 26 %), developmental dysplasia of hip (6/34, 18 %), femoral neck fracture (5/34, 15 %), and osteoarthritis secondary to trauma (2/34, 6 %). The proportion of underlying diseases was similar in the two groups and laterality of arthroplasty and use of bearing material and bone cement was also matched in all three patient groups ( Table 1) .
All patients had a standard radiograph of the pelvis and a lateral radiograph of the hip. The prosthesis was deemed stable when neither symptoms nor radiographic finding of osteolysis were evident [6, 8] . The THA was considered to have late loosening when at least one component required replacement, and the indication for the revision surgery was the correction of pain and periprosthetic osteolysis. Computer tomography imaging was performed to confirm loosening of the prosthesis. The severity of osteolysis in the radiograph was evaluated according to the classification system of Gruen et al. [9] (dividing femur osteolysis into seven regions of interest [ROI] ) and the DeLee and Charley criteria (grading periacetabular bone resorption into three ROI) [10] . Focal osteolysis was graded by assigning a score of 0 to 3 to each ROI as follows: 0, no osteolysis; 1, osteolysis less than two millimetres; 2, osteolysis between two and ten millimetres; 3, osteolysis greater than ten millimetres [6] . The total osteolysis score (OS) was 30. The Harris hip score [11] showing the clinical results of THA and the duration of follow-up (years) of the three groups were also recorded ( Table 1) .
Immunoenzymatic assay
Whole peripheral blood was collected in tubes containing EDTA (K2) (Yangpu, Guangzhou, China) and centrifuged at 3,000 rpm for two minutes within two hours of sampling to prevent disruption of cells from contaminating intracellular or induced cytokines. Plasma was separated immediately and placed in another tube. Processed plasma contained approximately 0.47-45.4×10 6 leucocytes [12] . To prevent leucocyte contamination, the plasma was recentrifuged at 13,000 rpm for five minutes, transferred to plastic cuvettes, and stored at −80°C until analysis. In patients who underwent revision THA for AL, blood samples were collected the day before surgery so that any immunological changes due to anaesthesia would be avoided. All sample collection, sample preparation, and immunoenzymatic assays were performed by the same research personnel. The OPG concentration was measured using an instant human enzyme-linked immunosorbent assay (ELISA) (eBioscience, Bender MedSystems GmbH, Vienna, Austria). An anti-human OPG polyclonal coating antibody was absorbed onto microwells. Human OPG binds to the antibody before a biotin-conjugated polyclonal anti-human OPG antibody binds to the human OPG. The standard reference is between 2.5 and 1,000 pg/ml. RANKL was measured using a Milliplex map human single plex ELISA kit (Millipore Corp, MA, USA). The luminex technology uses microspheres with two fluorescent dyes, which allows more precise calculation of the RANKL concentration than routine spectrophotometry. The standard reference was between 4.8 and 5,000 pg/ml, with an intra-assay coefficient of variation (CV) less than 7 %, and inter-assay CV less than 8 %. NTX was measured using a human sandwich ELISA kit (MyBioSource, CA, USA). The results were expressed as nanoMole of bone collagen equivalents per litre (nMBCE/L). The standard reference was between 2 and 500 nMBCE/L without significant cross-reactivity or interference. PICP was measured using a quantitative human sandwich ELISA kit (BlueGene Biotech, Shanghai, China). The standard reference was between 0.1 and 25 ng/ml, with intra-assay CV less than 10 % and inter-assay CV less than 12 %. There was no significant cross-reactivity or interference. TNF-α was measured using a human sandwich ELISA kit (Quantikine, R&D Systems, MN, USA). The standard reference was between 1.6 and 1,000 pg/ml, with intraassay CV less than 4.6 %, and inter-assay CV less than 7.4 %. IL-1β was measured using a human sandwich ELISA kit (RayBiotech, NSW, Australia). The standard reference was between 0.3 and 100 pg/ml, with intra-assay CV less than 10 % and inter-assay CV less than 12 %.
The binding between protein and antibodies was detected by the following sequence of reactions: anti-human biotinylated antibody, streptavidin-peroxidase conjugates, and substrate (tetrabenzidine) reacting with peroxidase. The reaction was stopped with sulphuric acid and optical density read at 450 nm.
Statistical analysis
Quantitative results of the clinical variables were expressed as the mean and the standard error of mean (SEM), and tested by analysis of variance (Bonferroni test of ANOVA) using SPSS17.0 software (USA). Synthesising analysis of the continuous outcomes of six biomarkers with the total number of assigned participants as the denominator was performed using RevMan software (RevMan 5.1.2) from the Cochrane Collaboration [13] . For every comparison between different AL and control groups, the standardised mean difference (Hedges' adjusted SMD) was calculated as the effect size with a 95 % credible interval (CI) using a random-effects model to incorporate the assumption that the multiple biomarkers related to AL could estimate the intervention effects. We used visual inspection of forest plots to investigate SMD with p value in 95 % CI and the weight of each biomarker in the group. A secondary analysis of the efficacy of biomarkers in diagnosing AL was performed by the outcomes of heterogeneity (shown by p value from a chi-square test), and when the value of I 2 was lower than 50 %, the heterogeneity was thought to be very low [14] .
Results
In all groups, there were no differences with regard to the age, gender, indication for total hip arthroplasty, laterality of THA, prosthetic material, or use of bone cement (data not shown). However, Harris hip score was lowest and OS including femoral and acetabular OS was highest in the late AL group, followed by the early AL and stable group (Bonferroni test of AVONA, all p<0.01). The follow-up years was significantly longer in the late AL than in the other two groups who were nearly the same (Bonferroni test of AVONA, all p<0.01) ( Table 1) .
The plasma level of OPG, RANKL, NTX, TNF-α, and IL1βLwere highest in the late AL group, followed by the early AL, stable and healthy groups. The level of PICP was highest in the healthy group, followed by the stable, early AL and late AL groups. The synesthetic analysis showed the plasma levels of six biomarkers were significantly different between the stable and healthy groups, and between the late AL and stable groups (both p=0.02). The outcomes of PICP were shown by negative value because it changes reversely in relation to the other five markers. The heterogeneity of the six biomarkers is not significant (p>0.05) and very low (I 2 =0) in both comparisons ( Figs. 1 and 2 ). But there was no significant difference between the early AL group and the stable (Fig. 3) Patients who had cemented implants had significantly longer post-operative years (ANOVA, p=0.031), lower Harris hip score (p=0.005), higher OS (P=0.013), higher acetabular OS Fig. 1 Synthetic analysis of plasma level of six biomarkers between the aseptic loosening (AL) and stable groups Fig. 2 Synthetic analysis of plasma level of six biomarkers between the stable and healthy groups (p=0.025), higher femur OS (p=0.019), and higher level of TNF-α (p=0.042) than patients with cementless hips (Table 2) . But the plasma level of the other five biomarkers had no significant differences between the two groups.
Discussion
Despite the enormous success rates of hip arthroplasty, patients face a number of potential complications, including periprosthetic osteolysis, implant loosening, and joint infections. Osteolysis and subsequent aseptic joint loosening is the most common reason for joint revision [15] .
Diagnostic and prognostic biomarkers have the potential to provide an early, accurate, and noninvasive diagnosis of these undesired outcomes as well as help design interventions to prevent some of these complications, especially AL.
There has been a great variability reported in the use of biomarkers to diagnose AL. The majority of these studies were case control studies with small sample sizes, and with few biomarkers investigated [3, 4, 7, 15, 16] . This type of evaluation was prone to type I error (false positive result). So it is necessary for the study to include multiple biomarkers (at least six) and simultaneously consist of at least 100 patients or healthy donors in AL of THA. Fig. 3 Synthetic analysis of plasma level of six biomarkers between the early aseptic loosening (AL) and stable groups Immune inflammatory responses and macrophage release of proinflammatory cytokines IL-1β and TNF-α [17, 18] (induced by phagocytosis of periprosthetic particle) directly induce fibroblast proliferation and tissue necrosis, and stimulate activation and proliferation of newly formed macrophages, osteoblasts (whose surface has OPG), and osteoclasts (mediated by RANKL) around the implant [19] . This causes increased bone resorption (reflected by blood NTX) or abnormal bone formation (reflected by blood PICP) [7, 20] . Periprosthetic bone resorption, increased local debris, macrophage activation, systemic proinflammatory cytokine synthesis, osteoblast activation, pain, and complete prosthetic loosening constitute the cycle of AL [4] [5] [6] . These studies showed IL-1β, TNF-α, OPG, RANKL, PICP and NTX are important biomarkers in AL of THA. But it is not known which is best in the evaluation of AL and if they affect AL in different degrees in different stages of AL. As we know, there has been no study simultaneously comparing the six biomarkers in AL.
Although most biomarkers are sensitive in many pathological processes such as the initial stage after THA, the level of biomarkers in serum or plasma is usually very low [21] and difficult to use in the early detection of AL. So we postulated that synthesised analysis of multiple biomarkers would be more effective in reflecting AL than any single test, because multiple positive factors increase the probability of detection of disease clinical practice. In our study the plasma level of OPG, TNF-a, NTX, RANKL and IL-1βall was from high to low in the late AL, early AL, stable and healthy groups. And PICP changed inversely in four groups. Although any single biomarkers showed no significant differences between the AL and control groups, synthetic analysis of six markers showed that there was a significant difference between the stable and healthy groups and between the late AL and stable groups. Furthermore, there was extremely low heterogeneity among different outcomes of biomarkers in our study (I 2 was zero). Our results supported the finding of the former study that OPG, TNF-a, NTX, RANKL and IL-1β were related to AL, especially severe AL [4] [5] [6] . Furthermore, it was such that in the stable group the clinical and radiographic method could not detect the existence of AL; the synthetic analysis of multiple biomarkers showed significant difference compared to healthy donors. So the six biomarkers analysis may be better than the traditional method in diagnosing AL. But further long-term prospective or multi-centre studies are needed to further confirm our findings.
Measuring periprosthetic BMD in subjects with failed implants is technically more difficult than in subjects with fixed implants. Scan analysis can be difficult because of the destruction of bony landmarks or change in position of implanted landmarks [22, 23] . We selected the bone resorption marker NTX and bone formation marker PICP to reflect the bone turnover process. We found reduced plasma NTX levels and increased PICP levels in patients with late loosening, early loosening, and stable prostheses, compared to healthy donors. Furthermore our results showed the SMD of PICP was higher in the AL group than in the stable group according to other markers. These findings indicate that bone formation in patients of AL quickly decreases as loosening of the arthroplasty develops, as Granchi et al. found [5] .
The receptor activator of nuclear factor-kB ligand (RANKL) is a member of the TNF superfamily. It appears to play an important role in both immune responses and bone morphogenesis [24, 25] . The ratio of the expression of RANKL to OPG is critical to the outcome of bone resorption [26] . Kim et al. [27] demonstrated decreased levels of OPG in failed THA. We found the plasma level of OPG increased in AL. OPG level may reflect a protective mechanism of the skeleton to increased bone resorption. This defence inhibits osteoclast formation and bone resorbing activity in AL [6, 28] . In confirmation, the SMD of biomarkers in our study showed OPG including RANKL acted mainly in the early stage of AL compared to other proinflammatory or bone turnover biomarkers. However, the systemic proinflammatory cytokine IL-1β was more pronounced in the severe stage of AL of THA than the two key meditative factors of AL. These results may explain why there was much variability about the same biomarker in a similar study.
In our study, OS including acetabular and femur OS were all significantly higher and yet Harris hip scores were significantly lower in cemented THA than in cementless THA. At the same time, plasma levels of TNF-α were significantly higher in patients with cemented prostheses than those with cementless varieties. These results suggest that cement promoted the release of proinflammatory cytokines such as TNF-α both locally and systematically, leading to prosthetic osteolysis in total hip arthroplasty [29] . But the postoperative years of cemented THA was significantly longer than that of cementless hips in this study, so further study including more samples to confirm the conclusion is needed. A problem with using biomarkers is the high level of intra-individual variability [30] . And the Elisa kits we used came from different manufacturers, which facilitated the collection of kits, but made the stability and coherence of test methods difficult to guarantee. This study emphasises synthetic biomarkers analysis is superior to the conventional test methods in early diagnosis of AL of THA, (because of the development of high throughput protein chip [21, 31] techniques containing multiple markers and giving prompt results), are good for the combination analysis of multiple biomarkers.
